PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
1.540
-0.050 (-3.14%)
At close: Apr 24, 2026, 4:00 PM EDT
1.550
+0.010 (0.65%)
After-hours: Apr 24, 2026, 7:25 PM EDT
PepGen Employees
PepGen had 56 employees as of December 31, 2025. The number of employees decreased by 25 or -30.86% compared to the previous year.
Employees
56
Change
-25
Growth
-30.86%
Revenue / Employee
n/a
Profits / Employee
-$1,600,982
Market Cap
106.44M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 56 | -25 | -30.86% |
| Sep 30, 2025 | 57 | -19 | -25.00% |
| Jun 30, 2025 | 62 | -10 | -13.89% |
| Mar 31, 2025 | 79 | 14 | 21.54% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Sep 30, 2024 | 76 | 13 | 20.63% |
| Jun 30, 2024 | 72 | 18 | 33.33% |
| Mar 31, 2024 | 65 | 16 | 32.65% |
| Dec 31, 2023 | 64 | 19 | 42.22% |
| Sep 30, 2023 | 63 | 23 | 57.50% |
| Jun 30, 2023 | 54 | 18 | 50.00% |
| Mar 31, 2023 | 49 | 18 | 58.06% |
| Dec 31, 2022 | 45 | 14 | 45.16% |
| Sep 30, 2022 | 40 | 17 | 73.91% |
| Jun 30, 2022 | 36 | 24 | 200.00% |
| Mar 31, 2022 | 31 | 19 | 158.33% |
| Dec 31, 2021 | 31 | - | - |
| Sep 30, 2021 | 23 | - | - |
| Jun 30, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| InflaRx | 65 |
| Vivani Medical | 42 |
| Genelux | 26 |
| Cognition Therapeutics | 14 |
| ProMIS Neurosciences | 11 |
| Coya Therapeutics | 8 |
PEPG News
- 25 days ago - PepGen Transcript: Study update - Transcripts
- 25 days ago - PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 26 days ago - PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - Business Wire
- 6 weeks ago - PepGen Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - US FDA puts partial clinical hold on PepGen's muscle disease drug trial - Reuters
- 7 weeks ago - PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights - Business Wire
- 7 weeks ago - PepGen Announces Regulatory Updates on FREEDOM2 - Business Wire
- 7 weeks ago - PepGen to Participate in the Leerink Global Healthcare Conference - Business Wire